# Pituitary Adenomas - Evaluation and Management

## Epidemiology and Classification

### Prevalence and Incidence

Pituitary adenomas are among the most common intracranial neoplasms, accounting for 10 to 15% of all tumors identified within the cranium. Autopsy and incidental imaging studies have revealed a remarkably high prevalence of 10 to 20%, indicating that the vast majority of pituitary adenomas are clinically silent and never come to medical attention. The clinically relevant prevalence, encompassing tumors that produce symptoms through hormonal hypersecretion or mass effect, is approximately 1 in 1,000 in the general population.

The peak incidence of pituitary adenomas spans the third through sixth decades of life. There is a slight female predominance for prolactinomas and Cushing disease, likely reflecting both biological susceptibility and patterns of clinical presentation that lead to earlier diagnosis in women. Pituitary carcinoma is exceedingly rare, representing fewer than 0.2% of all pituitary tumors. Its diagnosis requires the demonstration of craniospinal or systemic metastases, as there are no histological features that reliably distinguish carcinoma from adenoma in the absence of metastatic spread.

### 2017 WHO Classification Updates

The 2017 World Health Organization classification represented a fundamental shift in how pituitary adenomas are categorized, moving from a system based primarily on hormone immunostaining to one grounded in anterior pituitary cell lineage as determined by transcription factor expression. This lineage-based approach better reflects the biology and clinical behavior of these tumors.

| Lineage | Transcription Factor | Adenoma Types | Hormones Produced | Clinical Significance |
|---|---|---|---|---|
| Pit-1 | POU1F1 | Somatotroph, Lactotroph, Thyrotroph, Mammosomatotroph | GH, Prolactin, TSH | Most common functioning adenomas |
| T-pit | TBX19 | Corticotroph (functioning and silent) | ACTH | Silent forms may be aggressive |
| SF-1 | NR5A1 | Gonadotroph | LH, FSH, subunits | Majority of clinically non-functioning adenomas |
| Null cell | None identified | Null cell | None | Separate category; diagnosis of exclusion |

The Pit-1 lineage encompasses somatotroph, lactotroph, thyrotroph, and mammosomatotroph adenomas, all of which derive from progenitor cells that express the Pit-1 transcription factor. The T-pit lineage includes corticotroph adenomas, both functioning (Cushing disease) and clinically silent varieties that may demonstrate aggressive behavior. The SF-1 lineage comprises gonadotroph adenomas, which constitute the majority of clinically non-functioning pituitary adenomas. Null cell adenomas, which lack expression of any identifiable transcription factor or hormone, represent a separate category.

The classification also introduced important prognostic refinements. The previous term "atypical adenoma" was replaced by "high-risk adenoma," characterized by a Ki-67 proliferative index exceeding 3%, elevated mitotic count, and p53 immunopositivity. Plurihormonal adenomas of the Pit-1 lineage, previously designated as "silent subtype 3" adenomas, were recognized as particularly aggressive tumors warranting close surveillance.

### Size Classification

Pituitary adenomas are classified by size into microadenomas (less than 10 mm), macroadenomas (10 mm or greater), and giant adenomas (40 mm or greater). The Knosp classification system grades the degree of cavernous sinus invasion on a scale of 0 to 4, based on the relationship of the tumor to tangent lines drawn along the intracavernous and intercavernous portions of the internal carotid artery. Higher Knosp grades predict lower rates of surgical cure and inform the decision-making process regarding surgical approach and expectations.

## Clinical Presentation

### Mass Effect Symptoms

The clinical presentation of pituitary adenomas reflects the interplay between hormonal hypersecretion (when present) and the mechanical consequences of tumor growth within the confined space of the sella turcica and its surrounding structures.

Visual field defects are the hallmark of suprasellar extension. The classic pattern is bitemporal hemianopia, resulting from compression of the decussating nasal retinal fibers at the optic chiasm. In practice, the field defect is often asymmetric, and superior temporal quadrantanopia is frequently the earliest detectable abnormality. All patients with macroadenomas require formal visual field testing using Goldman or Humphrey automated perimetry rather than bedside confrontation testing alone.

Headache is reported by 40 to 60% of patients with pituitary adenomas but correlates poorly with tumor size. The pain may be mediated by dural stretch or cavernous sinus involvement and can occur even with small tumors. Cranial nerve palsies result from lateral tumor extension into the cavernous sinus, with cranial nerve III being the most commonly affected, followed by nerves IV, VI, V1, and V2.

Hypopituitarism develops from compression of normal pituitary tissue and correlates with tumor size. GH and gonadotropin deficiency tend to develop first, followed by TSH and ACTH deficiency. Pituitary apoplexy, an acute hemorrhage or infarction within a pituitary adenoma, constitutes an endocrine emergency characterized by sudden severe headache, visual loss, ophthalmoplegia, and potential hemodynamic compromise. CSF rhinorrhea is uncommon but may occur, particularly in association with empty sella or following surgical intervention.

### Hormonal Hypersecretion Syndromes

Prolactinomas are the most common functioning pituitary adenomas, accounting for 40 to 45% of all pituitary tumors. In women, they typically present as microadenomas with amenorrhea, galactorrhea, and infertility. In men, the presentation is often delayed until the tumor reaches macroadenoma size, presenting with erectile dysfunction, decreased libido, and mass effect symptoms.

GH-secreting adenomas cause acromegaly in 10 to 15% of pituitary tumors. The clinical features develop insidiously over years and include progressive coarsening of facial features, acral enlargement, hyperhidrosis, carpal tunnel syndrome, obstructive sleep apnea, diabetes mellitus, and cardiomyopathy. ACTH-secreting adenomas cause Cushing disease in 5 to 10% of cases, manifesting with central obesity, proximal myopathy, wide purple striae, easy bruising, hypertension, diabetes, and accelerated osteoporosis. TSH-secreting adenomas are the rarest functioning subtype at 1 to 2%, presenting with hyperthyroidism in the setting of a non-suppressed or elevated TSH, a biochemical pattern that must be carefully distinguished from thyroid hormone resistance.

<image>A composite clinical illustration showing four panels depicting the major functioning pituitary adenoma syndromes. Panel A: Prolactinoma - showing a female patient with galactorrhea and amenorrhea, with an inset MRI showing a microadenoma. Panel B: Acromegaly - showing characteristic facial features (frontal bossing, prognathism, widened nose, thick lips), enlarged hands, and skin tags. Panel C: Cushing disease - showing moon facies, central obesity, purple striae on abdomen, thin extremities, and buffalo hump. Panel D: TSH-secreting adenoma - showing diffuse goiter with an inset of elevated T4 with non-suppressed TSH on laboratory display. Use realistic medical illustration style.</image>

## Diagnostic Evaluation

### Biochemical Workup - All Pituitary Adenomas

Every patient with a pituitary adenoma, regardless of size or presumed functional status, requires a comprehensive biochemical evaluation to assess for hormonal hypersecretion and hypopituitarism.

Serum prolactin measurement is essential and must be interpreted carefully in the context of tumor size. The "hook effect," a laboratory artifact caused by antibody saturation in immunometric assays, can produce falsely low prolactin levels in patients with giant prolactinomas. When a macroadenoma is identified but the prolactin level is unexpectedly low (below 200 ng/mL), serial dilutions of the sample should be specifically requested to unmask this artifact.

IGF-1, measured using age- and sex-matched reference ranges, serves as the screening test for GH excess. When elevated, the diagnosis of acromegaly should be confirmed with an oral glucose tolerance test, in which failure of GH to suppress below 1 ng/mL on current assays (or below 0.4 ng/mL with ultrasensitive assays) confirms autonomous GH secretion. For suspected Cushing disease, an initial morning cortisol and ACTH should be obtained, followed by at least two screening tests from among 24-hour urinary free cortisol, late-night salivary cortisol, or the 1 mg overnight dexamethasone suppression test.

Free T4 and TSH are measured to evaluate both central hypothyroidism (low free T4 with inappropriately normal or low TSH) and the rare TSH-secreting adenoma (elevated free T4 with non-suppressed TSH). Gonadal axis assessment with LH, FSH, and sex steroids helps identify both hypogonadism from compression and gonadotroph adenomas, which may show elevated FSH or LH levels. Alpha subunit measurement can support the diagnosis of gonadotroph adenomas and TSH-secreting adenomas.

### Imaging

MRI with gadolinium enhancement is the gold standard imaging modality for pituitary lesions. A dedicated pituitary protocol employing thin (2 to 3 mm) coronal and sagittal cuts through the sella is essential, as standard brain MRI sequences may miss small lesions. Dynamic contrast-enhanced sequences are particularly valuable for detecting microadenomas, which characteristically enhance later than normal pituitary tissue and appear as hypointense foci on early post-contrast images.

For macroadenomas, the MRI assessment must systematically evaluate suprasellar extension and its relationship to the optic chiasm, lateral extension into the cavernous sinuses with Knosp grading, and inferior extension into the sphenoid sinus. CT scanning is inferior to MRI for soft tissue characterization but provides valuable information about the bony anatomy of the sphenoid sinus for surgical planning, and serves as an alternative when MRI is contraindicated.

### Visual Assessment

Formal visual field testing using automated perimetry is mandatory for all macroadenomas, particularly those with suprasellar extension. Optical coherence tomography (OCT) of the retinal nerve fiber layer has emerged as an important complementary tool, providing an objective quantitative measure of optic nerve damage that is useful both for baseline assessment and longitudinal monitoring. Thinning of the retinal nerve fiber layer on OCT may predict suboptimal visual recovery following surgical decompression.

## Management of Specific Tumor Types

### Prolactinomas

The management of prolactinomas is unique among pituitary adenomas in that medical therapy with dopamine agonists is the first-line treatment, even for macroadenomas. This reflects the exquisite sensitivity of most prolactinomas to dopaminergic suppression.

| Feature | Cabergoline | Bromocriptine |
|---|---|---|
| Dosing | 0.25-0.5 mg twice weekly (maintenance 1-2 mg/week) | 2.5-15 mg daily |
| Efficacy (PRL normalization) | ~85-90% | ~70-80% |
| Tumor shrinkage (>25%) | 80-90% of macroprolactinomas | 60-70% |
| Tolerability | Better (fewer GI side effects) | More GI side effects |
| Resistance dose threshold | >3.5 mg/week | N/A |
| Pregnancy safety data | Less extensive | Longer track record (preferred in pregnancy) |
| Valvulopathy concern | Low risk at endocrine doses (<2 mg/week) | Not significant |

Cabergoline is the preferred dopamine agonist due to its superior efficacy, better tolerability, and more convenient dosing schedule compared to bromocriptine. Treatment is typically initiated at 0.25 to 0.5 mg twice weekly and titrated upward to normalize prolactin levels, with typical effective doses of 1 to 2 mg per week. Bromocriptine, dosed at 2.5 to 15 mg daily, remains an important alternative, particularly during pregnancy, where its longer safety track record confers a degree of reassurance. Tumor shrinkage of greater than 25% is achieved in 80 to 90% of macroprolactinomas treated with dopamine agonists, often with dramatic improvement in visual fields occurring within days to weeks.

Dopamine agonist resistance, defined as failure to normalize prolactin levels or achieve greater than 50% tumor volume reduction on maximally tolerated cabergoline doses (typically 3.5 mg per week or more), occurs in approximately 10 to 15% of patients. The concern regarding cardiac valvulopathy with cabergoline, well documented at the high doses used for Parkinson disease (exceeding 3 mg per day), appears to carry low clinical risk at the much lower doses used in endocrine practice. Nonetheless, echocardiographic surveillance should be considered for patients receiving more than 2 mg per week for prolonged durations.

Surgery is reserved for patients with dopamine agonist-resistant tumors, those who cannot tolerate medical therapy, those with CSF leaks, patients with predominantly cystic tumors that respond poorly to dopamine agonists, and those who prefer surgical management. Withdrawal of dopamine agonist therapy may be attempted after two or more years of treatment if prolactin has normalized and significant tumor shrinkage has been achieved, although recurrence rates of 30 to 50% should be discussed with patients.

### GH-Secreting Adenomas (Acromegaly)

In contrast to prolactinomas, transsphenoidal surgery is the first-line treatment for most patients with acromegaly. Remission rates are strongly dependent on tumor size and surgical expertise, ranging from 80 to 90% for microadenomas to 40 to 60% for macroadenomas when performed by experienced pituitary surgeons. Biochemical targets for remission include normalization of age-matched IGF-1 and a random GH level below 1.0 ng/mL or a GH nadir below 0.4 ng/mL on oral glucose tolerance testing.

For patients with persistent disease after surgery, first-generation somatostatin receptor ligands (SRLs) such as octreotide LAR (10 to 40 mg every 4 weeks) and lanreotide Autogel (60 to 120 mg every 4 weeks) normalize IGF-1 in approximately 35 to 45% of patients. Pasireotide LAR, which targets SSTR5 in addition to SSTR2, achieves a modestly higher biochemical control rate (approximately 15 to 20% more) but carries a significant risk of hyperglycemia, with over 60% of patients developing glucose intolerance or diabetes during treatment.

Pegvisomant, a GH receptor antagonist administered as 10 to 30 mg subcutaneously daily, offers the highest biochemical efficacy, normalizing IGF-1 in up to 90% of patients. However, it does not shrink the tumor and requires monitoring of liver function tests. Cabergoline provides modest efficacy as monotherapy (approximately 30% in patients with mildly elevated IGF-1) and is useful as an adjunctive agent. Combination therapy, such as an SRL with pegvisomant or an SRL with cabergoline, is employed for refractory cases. Radiation therapy is reserved for residual or recurrent disease that is not controlled by surgery and medical therapy.

### ACTH-Secreting Adenomas (Cushing Disease)

Transsphenoidal surgery by an experienced pituitary neurosurgeon is the first-line treatment for Cushing disease, achieving remission rates of 70 to 90% for microadenomas. When MRI fails to identify a definitive adenoma, or when biochemical confirmation of a pituitary source is needed, inferior petrosal sinus sampling (IPSS) is indicated. A central-to-peripheral ACTH ratio of 2 or greater at baseline, or 3 or greater after CRH administration, confirms a pituitary source with high sensitivity and specificity. Repeat surgery is an option for recurrent disease, though with a lower remission rate of approximately 50 to 70%.

| Drug | Class | Dose | Efficacy (UFC normalization) | Key Side Effects |
|---|---|---|---|---|
| Ketoconazole | Steroidogenesis inhibitor | 200-400 mg BID-TID | ~50% | Hepatotoxicity, GI upset |
| Metyrapone | Steroidogenesis inhibitor | 250-1000 mg TID-QID | ~50% | Hirsutism, hypertension |
| Osilodrostat | Steroidogenesis inhibitor | 2-7 mg BID | ~65% | Adrenal insufficiency, QTc prolongation |
| Pasireotide | Pituitary-directed (SRL) | 0.6-0.9 mg SC BID or 10-40 mg LAR monthly | ~25% | Hyperglycemia (>60%) |
| Cabergoline | Pituitary-directed (DA) | 1-7 mg weekly | 25-35% | GI upset, valvulopathy risk at high doses |
| Mifepristone | GR antagonist | 300-1200 mg daily | Clinical improvement (cannot follow cortisol) | Cortisol rises; monitor clinically |

Medical therapy for Cushing disease encompasses three mechanistic categories. Steroidogenesis inhibitors include ketoconazole (200 to 400 mg two to three times daily, limited by hepatotoxicity risk), metyrapone (250 to 1000 mg three to four times daily), and osilodrostat (2 to 7 mg twice daily, with risks of adrenal insufficiency and QTc prolongation). Pituitary-directed agents include pasireotide (0.6 to 0.9 mg subcutaneously twice daily or 10 to 40 mg LAR monthly, normalizing urinary free cortisol in approximately 25% but causing significant hyperglycemia) and cabergoline (1 to 7 mg weekly, with a 25 to 35% response rate). The glucocorticoid receptor antagonist mifepristone (300 to 1200 mg daily) is specifically indicated for the hyperglycemia of Cushing syndrome, though monitoring relies on clinical parameters rather than cortisol levels, as cortisol will paradoxically rise during treatment.

Bilateral adrenalectomy provides definitive control of hypercortisolism in refractory cases but carries the risk of Nelson syndrome, in which the residual corticotroph tumor undergoes progressive enlargement in the absence of cortisol-mediated negative feedback, occurring in approximately 15 to 25% of patients. Radiation therapy, whether stereotactic radiosurgery or fractionated, achieves remission in 50 to 60% of patients over 3 to 5 years, with hypopituitarism as the principal long-term complication.

### Clinically Non-Functioning Pituitary Adenomas (NFPAs)

The majority of clinically non-functioning pituitary adenomas are gonadotroph adenomas expressing SF-1, which produce LH, FSH, or their subunits but at levels insufficient to cause a clinical syndrome. Surgery is indicated when the tumor causes visual field compromise, demonstrates progressive growth, or presents with pituitary apoplexy. For incidental macroadenomas without visual compromise, observation with serial imaging is a reasonable strategy, beginning with repeat MRI at 6 months and then annually. Visual field testing should be performed whenever a tumor approaches the optic chiasm.

Following surgical resection, a new baseline MRI is obtained at 3 to 6 months and then annually for 5 years, with decreasing frequency thereafter if stable. Recurrence rates of 15 to 50% at 10 years underscore the need for prolonged surveillance. Radiation therapy is reserved for tumors demonstrating residual growth or recurrence after surgery.

<image>A diagnostic and management algorithm for a newly discovered pituitary macroadenoma. Start with initial biochemical workup (prolactin, IGF-1, morning cortisol, free T4/TSH, LH/FSH, testosterone/estradiol). Branch based on results: if prolactin >200 ng/mL, pathway leads to dopamine agonist therapy; if IGF-1 elevated, pathway leads to OGTT confirmation then surgery; if Cushing suspected, pathway leads to screening tests then IPSS if needed then surgery; if non-functioning, pathway branches based on visual field status (compromised leads to surgery, normal leads to observation with serial MRI). Include a box for post-surgical management with MRI and hormonal follow-up. Use clean flowchart format with color-coded pathways for each tumor type.</image>

## Surgical Approaches

### Transsphenoidal Surgery (TSS)

Transsphenoidal surgery remains the cornerstone of pituitary surgical management, and two primary approaches are in widespread use. The endoscopic endonasal approach is increasingly preferred, offering wider visualization, improved illumination of the operative field, and lower nasal morbidity compared to the traditional microscopic technique. The microscopic sublabial or transnasal approach remains widely used and provides excellent outcomes in experienced hands. Extended transsphenoidal approaches have been developed for giant adenomas with significant suprasellar extension, and intraoperative MRI is an emerging tool that allows real-time assessment of the extent of resection.

The complications of transsphenoidal surgery, while relatively infrequent in experienced centers, warrant careful attention in postoperative management. CSF leaks occur in 1 to 4% of cases and may require surgical repair. Transient diabetes insipidus occurs in 10 to 20% of patients, while permanent DI develops in only 1 to 3%. New pituitary hormone deficiencies arise in 5 to 10% of cases. Carotid artery injury and meningitis are rare but potentially devastating complications, each occurring in fewer than 1% of procedures. The "triple-phase response," consisting of initial DI followed by a phase of SIADH (typically on days 5 to 10) and then a return of DI, is an important postoperative phenomenon that requires vigilant sodium monitoring for 7 to 14 days following surgery.

### Craniotomy

Craniotomy is reserved for tumors with significant lateral extension beyond the cavernous sinus or predominantly suprasellar tumors with a dumbbell configuration that cannot be adequately accessed through the transsphenoidal corridor. This approach carries higher morbidity than transsphenoidal surgery and is employed only when the anatomy precludes a transphenoidal approach.

## Radiation Therapy

### Types

Several radiation modalities are available for pituitary tumors, each with specific indications and technical requirements. Stereotactic radiosurgery (SRS), delivered via Gamma Knife, CyberKnife, or LINAC-based platforms, delivers a single high-dose fraction (typically 12 to 25 Gy marginal dose) with high conformality. This approach requires a tumor margin at least 3 to 5 mm from the optic chiasm to avoid optic neuropathy. When the tumor is too close to the chiasm, fractionated stereotactic radiotherapy (FSRT), delivering 45 to 54 Gy in 25 to 30 fractions, provides an alternative with a more favorable therapeutic ratio for adjacent critical structures. Proton beam therapy offers theoretically superior dose conformality due to the Bragg peak effect but has limited availability.

### Outcomes and Complications

Both SRS and FSRT achieve excellent tumor control rates exceeding 90% at 10 years. Hormonal normalization in functioning adenomas occurs more gradually, with 50 to 70% of GH- and ACTH-secreting adenomas achieving biochemical remission over 5 to 10 years. The most common long-term complication is hypopituitarism, developing in 30 to 50% of patients by 10 years and necessitating lifelong hormonal surveillance. Optic neuropathy occurs in fewer than 5% of patients with modern treatment planning that limits the dose to the chiasm below 8 Gy in single-fraction delivery. Secondary tumors, most commonly meningiomas, represent a very low risk of less than 2% at 20 years. A small but measurable increase in cerebrovascular events has been observed years after conventional radiotherapy, though this risk appears lower with modern conformal techniques.

## Aggressive Pituitary Tumors and Carcinoma

### High-Risk Features

Certain pituitary tumors demonstrate aggressive behavior characterized by rapid growth despite standard therapy and invasion of surrounding structures. Histopathological features associated with aggressive behavior include a Ki-67 proliferative index exceeding 3%, elevated mitotic count, and p53 immunopositivity. Specific histological subtypes with a recognized propensity for aggressive behavior include sparsely granulated somatotroph adenomas, Crooke cell corticotroph adenomas, silent corticotroph adenomas, and Pit-1 plurihormonal adenomas. Male prolactinomas with high Ki-67 indices may also behave aggressively and warrant close surveillance.

### Temozolomide

Temozolomide, an oral alkylating agent, has emerged as the first-line chemotherapy for aggressive pituitary tumors and pituitary carcinoma, fundamentally altering the management of these previously treatment-resistant conditions. The standard dosing regimen is 150 to 200 mg/m2 for 5 days of each 28-day cycle, with a minimum of 3 cycles administered before response is assessed. Overall response rates (partial or complete) are approximately 35 to 40%. The MGMT (O6-methylguanine-DNA methyltransferase) promoter methylation status has predictive value, with low MGMT expression correlating with better treatment response. The combination of capecitabine and temozolomide (CAPTEM) is an emerging regimen under investigation for refractory cases.

## Key Clinical Pearls

- Always check prolactin before surgery for any pituitary macroadenoma; a prolactinoma should be treated medically, not surgically, as first-line
- The "hook effect" can cause falsely low prolactin levels in giant prolactinomas; always request serial dilutions if prolactin is unexpectedly low relative to tumor size
- Incidentally discovered pituitary microadenomas (<10 mm) with normal hormonal workup may be followed with a single repeat MRI at 12 months; if stable, no further imaging needed per Endocrine Society guidelines
- Post-operative transient DI occurs in 10-20% of TSS cases, but delayed hyponatremia (SIADH) at days 5-10 is often missed; educate patients on fluid restriction and sodium monitoring
- In Cushing disease with a negative MRI, IPSS is the definitive test; do not proceed to pituitary exploration without it
- Temozolomide has transformed the management of aggressive pituitary tumors; assess MGMT status before or during treatment

## References

1. Melmed S, et al. "Diagnosis and Treatment of Hyperprolactinemia: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2011;96(2):273-288.
2. Katznelson L, et al. "Acromegaly: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2014;99(11):3933-3951.
3. Nieman LK, et al. "Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline." J Clin Endocrinol Metab. 2015;100(8):2807-2831.
4. Lopes MBS. "The 2017 World Health Organization Classification of Tumors of the Pituitary Gland: A Summary." Acta Neuropathol. 2017;134(4):521-535.
5. Raverot G, et al. "European Society of Endocrinology Clinical Practice Guidelines for the Management of Aggressive Pituitary Tumours and Carcinomas." Eur J Endocrinol. 2018;178(1):G1-G24.